.png){kind=icon}
.png){kind=icon}
Return
Equilibrative nucleoside transporter 1 deficiency protects against diet-induced MASLD and is stage-associated in human liver disease
.png){kind=icon}
OA
AI
A
E
A
L
J
A
A
M
R
Y
R
C
R
M
B
M
S
S
DOI：10.1016/j.metabol.2026.156710.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Hepatic ENT1 expression exhibits stage-specific differences during MASLD progression in mice and humans. • ENT1 deficiency induces mild basal metabolic alterations in the liver. • ENT1 loss protects against diet-induced liver disease in association with reduced body weight and improved metabolic status. • Hepatic ENT1 expression correlates with insulin levels and HOMA-IR in humans with early MASLD. • Nucleoside transport emerges as a regulatory axis in metabolic liver disease.
Keywords:
ENT1
Nucleoside transport
Hepatic metabolism
MASLD
MASH progression
Insulin resistance
Journal
M
IF:
11.9
Papers:
9.6K
Citations:
2.1W
Organization
Cited Papers